ejpmr, 2024, 11(6), 152-155

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

<u>Review Article</u> ISSN 2394-3211 EJPMR

TRIAZOLO-THIADIAZINE AND THEIR DERIVATIVES AS A POTENTIAL BIOLOGICAL ACTIVITY: A REVIEW

*G. Nageswara Rao

Department of Chemistry and Research Centre, Telangana University, Nizamabad, Telangana-503322. India.



*Corresponding Author: G. Nageswara Rao

Department of Chemistry and Research Centre, Telangana University, Nizamabad, Telangana-503322. India.

```
Article Received on 07/04/2024
```

Article Revised on 28/04/2024

Article Accepted on 19/05/2024

ABSTRACT

Triazolothiadiazine-based scaffolds possess versatile medicinal uses such as antibacterial activity, antifungal activity, anti-inflammatory activity.



KEYWORDS: Triazolo-Thiadiazine, Anti-viral activity, Anti-fungal activity.

INTRODUCTION

The 1,2,4-triazole substituted with amino and mercapto groups have been reported to possess a variety of biological activities such as antibacterial^[1], antifungal^[2], antitubercular^[3], anticancer^[4], diuretic^[5], and hypoglycemic.^[6] The amino and mercapto groups are readymade nucleophilic centers for synthesis of fused heterocyclic systems.^[7] Further, the triazole fused with thiadiazine have promising biological activities such as

anti-HIV^[8], CNS stimulant^[9], antifungal^[10], antiinflammatory^[11] and anti *Candidal* activity.^[12]

BIOLOGICAL ACTIVITY

Triazolothiadiazine-based scaffolds possess versatile potent biological activity such as antibacterial activity, antifungal activity, antiviral activity and antiinflammatory activity. **Figure A.**



Figure 1: According to Vinod Kumar *et al.*^[13] the novel triazolo-thiadiazine derivatives **1** were synthesised and evaluation for their anti viral activity using two animal



viruses, *Japanese encephalitis virus* (JEV) strain P20778 and *herpes simplex virus-1* (HSV-1) strain 753166.



 $R_1 = H \text{ or phenyl}$

Figure 1.

Figure 2: Dihydroindeno and indeno[1,2-e][1,2,4]triazolo[3,4-b][1,3,4]thiadizines **2(a-I)** and **3(a-I)** were synthesised, and their effects on the *in vitro* growth of microorganisms that cause microbial infection were assessed by Om *et al.*^[14] *Staphylococcus aureus, Bacillus subtilis, Escherichia coli,* and *Pseudomonas aeruginosa* were the four strains tested

in vitro for antibacterial activity. *Aspergillus niger, Aspergillus flavus*, and *Penicillium species* were tested for antifungal activity. Some of these compounds out of all the ones that were tested for activity had antibacterial and antifungal activity that was noticeably higher than that of conventional antibiotics.



Figure 3: New triazolothiadiazines were synthesised, tested in vitro against different Candida species, and contrasted with ketoconazole, according to Mehlika et $al^{[15]}$ The triazolothiadiazine ring 4 compound with a cyclohexyl moiety and a 4-chlorophenyl substituent was discovered to be the most effective derivative against Candida albicans (ATCC 90028). It is evident that two functional components, namely the cycloaliphatic group the 4-chlorophenyl and substituent on the triazolothiadiazine ring, positively correlate with anticandidal activity. Using the MTT assay, the compounds were also examined for their cytotoxic effects.



Figure 4: Several new fused 1,2,4-triazole series **5**(a-e) has been synthesised and tested for the *in vitro* antibacterial activity. Intriguing antibacterial activity was demonstrated by the majority of the investigated compounds against *Staphylococcus aureus*. The *in vitro* cytotoxic activity of the most potent antibacterial agents, **5**(c-e), against human cancer cell lines was also tested. When compared to the norm, it was discovered that compounds **5c** and **5e** were more cytotoxic to the Hep-G2 cell line.^[16]



Figure 5: A number of fused 1,2,4-triazoles with six membered heterocycles **6**, **7**, and **8** were synthesised, according to El Shehry *et al.*^[17] The newly synthesised compounds were tested for their molluscicidal and anti-inflammatory properties. In a dose-dependent manner,

the compounds 6 and 8 demonstrated strong anti- inflammatory effects.



Figure 6: The synthesis of nitrophenylfurfurylidene-1,2,4-triazolo[3,4-*b*][1,3,4]thiadiazines and testing of their antibacterial and antiviral activities were reported by Holla *et al.*^[18] The 4-nitrophenyl and methyl groups in compound **9**, one of the investigated compounds, demonstrated excellent antibacterial activity against all the bacteria examined. Compared to Furacin, compound **9** has higher levels of antibacterial activity against *E. coli, S. aureus*, and *P. aeruginosa*. The remaining compounds antibacterial properties, however, were on par with those of furacin. Consequently, it is worthwhile to research these compounds for various biological functions.



Figure 7: A new series of 2-phenyl-3-(6-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4] thiadiazin-3-yl)-4H-4chromenone **10(a-j)** has been synthesized by the reaction of 3(4-amino-5-sulfanyl-4H-1,2,4-triazol-3-yl)-2-phenyl-4H-4-chromenone **7** with a variety of phenacyl bromides in ethanol under reflux.Nagaraj *et al.*^[19] All newly synthesized compounds were screened for their in vitro antibacterial activities against S. aureus, B. cereus and P. aeruginosa. Compounds **10d**, and **10h** were highly active against Bacillus cereus, compound **10a** was highly active whereas compounds **10b** and **10d** were moderately active against Staphylococcus aureus, compounds **10f** and **10h** was moderately active against Pseudomonas aureginosa.



CONCLUSION

This review outlined the triazolo-thiadiazine and their derivatives served as a resource for both basic and applied research on the subject.

CONFLICTS OF INTEREST

There are no conflicts to declare.

ACKNOWLEDGEMENTS

The author is thankful to the head, Department of Chemistry, Telangana University, Nizamabad, Telangana, India, for support and facilities provided.

REFERENCES

- Foroumadi, A.; Mansouri, S.; Kiani, Z.; Rahmani, A. "Synthesis and *in vitro* antibacterial evaluation of *N*-[5-(5-nitro-2-thienyl)-1,3,4-thiadiazole-2yl]pipera- zinylquinolones" *Eur. J. Med. Chem.*, 2003; *38*: 851-854.
- Rollas, S.; Kalyoncuoglu, N.; Sur Altiner, D.; Yegenoglu, Y. "5-(4-aminophen- yl)-4-substituted-2,4-dihydro-3H-1,2,4-triazole-3-thiones: synthesis and anti-bacterial and antifungal activities" *Pharmazie*, 1993; 48: 308-309.
- Mir, I.; Siddiqui, M. T.; Comrie, A. M. "Antituberculosis agents. V: α-[5-(5-nitro-2-furyl)-1,3,4-oxadiazol-2-ylthio] acethydrazide and related compounds" *J. Pharm. Sci.*, 1991; 80: 548-550.
- Holla, B, S.; Veerendra, B.; Shivananda, M. K.; Poojary, B. "Synthesis characterization and anticancer activity studies on some Mannich bases derived from 1,2,4-triazoles" *Eur. J. Med. Chem.*, 2003; *38*: 759-767.

- 5. Yale, H. L.; Piala. J. J. "Substituted s-triazoles and related compounds" *J. Med. Chem.*, *1966*; *9*: 42-46.
- Mhasalkar, M. Y.; Shah, M. H.; Nikam, S. T.; Anantanarayanan, K. G.; Deliwala, C. V. "4-Alkyl-5-aryl-4H-1,2,4-triazole-3-thiols as hypoglycemic agents" *J. Med. Chem.*, 1970; *13*: 672-674.
- Dyablo, O. V.; Alexander, F. P. "Synthesis and properties of *N*-aminoazolinethiones and *N*aminoazinethiones 2. Reactions" *Chem. Heterocycl. Comp.*, 1997; 33: 1003-1027.
- Al-Masoudi, I. A.; Al-Soud, Y. A.; Al-Salihi, N. J.; Al-Masoudi, N. A. "1,2,4-Triazoles: synthetic approaches and pharmacological importance" *Chem. Heterocycl. Comp.*, 2006; 467: 1635-1646.
- Zitouni, G. T.; Kaplancikli, Z. A.; Erol, K.; Kilic, F. S. "Synthesis and analgesic activity of some triazoles and triazolothiadiazines" *Il Farmaco*, 1999; 54: 218-223.
- Karabasanagouda, T.; Adhikari, A. V.; Shetty, N. S. "Synthesis and antimicrobial activities of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines carrying thioalkyl and sulphonyl phenoxy moieties" *Eur. J. Med. Chem.*, 2007; 42: 521-529.
- 11. Bhalla, M.; Hitkari, A.; Gujrati, V. R.; Bhalla, T. N.; Shanker, K. "Benzopyran-2-one derivatives: antiinflammatory, analgesic and antiproteolytic agents" *Eur. J. Med. Chem.*, 1994; 29: 713-717.
- Prakash, O.; Aneja, D. K.; Hussain, K.; Lohan, P.; Ranjan, P.; Arora, S.; Sharma, C.; Aneja, K. R. "Synthesis and biological evaluation of dihydroindeno and indeno[1,2-e] [1,2,4] triazolo[3,4-b] [1,3,4] thiadiazines as antimicro- bial agents" *Eur. J. Med. Chem.*, 2011; 46: 5065-5073.
- Vinod Kumar, P.; Zehra, T.; Sumerah, T.; Madhawanand, J. "Synthesis and biological evaluation of some novel 5-[(3-aralkyl amido/imidoalkyl)phenyl]-1,2,4-Triazolo[3,4-b]-1,3,4 Thiadiazines as Antiviral Agents" *Int. Scholarly Res. Network*, 2012; Article ID 760517.
- Om, P.; Deepak, K.; Aneja, K. H.; Poonam, L.; Pooja, R.; Sanjiv, A.; Chetan, S.; Kamal, R. A. "Synthesis and biological evaluation of dihydroindeno and indeno[1,2-e][1,2,4]triazolo [3,4b] [1,3,4] thiadiazines as antimicrobial agents" *Eur. J. Med. Chem.*, 2011; 46: 5065-5073.
- Mehlika, D.; Zafer, A. K.; Gulhan, T. Z.; Ahmet, O.; Gokalp, I.; Gulsen, A.; Safak, U. Y. "Synthesis and anticandidal activity of new triazolothiadiazine derivatives" *Eur. J. Med. Chem.*. 2011; 46: 5562-5566.
- Sahar, M. I. B.; Rasha, M. B. "Synthesis of some new [1,2,4] triazolo[3,4-b][1,3,4]thiadiazines and [1,2,4]triazolo[3,4-b][1,3,4] thiadiazoles starting from 5-nitro-2-furoic acid and evaluation of their antimicrobial activity" *Bioorg. Med. Chem.*, 2011; *19*: 4506-4512.
- El Shehry, M. F.; Abu Hashem, A. A.; El Telbani, E. M. "Synthesis of 3-((2,4-dichlorophenoxy)methyl)-1,2,4-triazolo (thiadiazoles and thiadiazines) as anti-

inflammatory and molluscicidal agents" *Eur. J. Med. Chem.*, 2010; 45: 1906-1911.

- Holla, B. S.; Akberali, P. M.; Shivananda, M. K. "Studies on nitrophenylfuran derivatives: Part XII. synthesis, characterization, antibacterial and antiviral activities of some nitrophenylfurfurylidene-1,2,4-triazolo [3,4-b]-1,3,4-thia- diazines" *Il Farmaco*, 2001; *56*: 919-927.
- 19. Nagaraj.A, Nageswara Rao.G, Synthesis and Antibacterial Activity of[1,2,4]triazolo[3,4-b][1,3,4] thiadiazine Scaffolds, *International Journal of Research in Engineering and Science (IJRES)*, January 2023; 11(1): 194-199.